(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. TearClear has initiated a phase 3 trial evaluating ...

BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated. TearClear ...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of ...

CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead ...

Among some local side effects of prostaglandin-associated periorbitopathy (PAP), deepening of the upper eyelid sulcus (DUES) is the most prominent clinical feature, and is one of the most significant ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of latanoprost ophthalmic solution, 0.005% (0.05 mg/mL). Glenmark’s latanoprost ophthalmic solution, 0.005% (0.05 mg/mL) is ...

Please provide your email address to receive an email when new articles are posted on . Most of us are familiar with the different classes of eye drops. Eye drops are ...

The Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is the fourth ophthalmic product launched by Glenmark. Marc Kikuchi, President & Business Head, North America at Glenmark, expressed enthusiasm ...